Beta-Blocker Selection for Atherosclerotic Ectasia of the Thoracic Aorta

Primary Beta-Blocker Options

The American Heart Association recommends metoprolol, propranolol, labetalol, or esmolol as first-line beta-blockers to reduce aortic wall stress by controlling blood pressure, heart rate, and the force of left ventricular ejection (dP/dt) 1, 2
For acute management, intravenous options include propranolol (0.05-0.15 mg/kg every 4-6 hours) 2, metoprolol (intravenous formulation) 1, 2, esmolol (loading dose 0.5 mg/kg over 2-5 minutes, followed by infusion 0.10-0.20 mg/kg/min) 1, 2, and labetalol (combined alpha- and beta-blocker) 1, 2
For chronic management, oral options include metoprolol 1, 3, propranolol 2, 3, and atenolol 2, 3

The American College of Cardiology recommends a heart rate target of <60 beats per minute 1
The European Society of Cardiology recommends a systolic blood pressure target of 100-120 mm Hg 1, 2

Esmolol has a short half-life, making it ideal for testing beta-blocker tolerance in patients with potential contraindications (asthma, COPD, borderline heart failure) 1, 2, 3
Labetalol provides combined alpha- and beta-blockade, offering potent control with a single agent 1
Metoprolol and atenolol are beta-1 selective agents, preferred in patients with mild reactive airway disease or COPD 3

The American Heart Association recommends excluding marked first-degree AV block (PR >0.24 seconds), second-degree, or third-degree AV block without pacemaker 3
Decompensated heart failure (rales, S3 gallop, signs of low output) is a contraindication to beta-blockade 3, 4

The American College of Cardiology recommends high-intensity statin therapy targeting LDL <70 mg/dL 5
Smoking cessation is a Class I recommendation 5
Blood pressure control to <140/90 mm Hg (or <130/80 mm Hg if diabetic or chronic kidney disease) is recommended 5

The European Society of Cardiology recommends calcium channel blockers (verapamil, diltiazem, nifedipine) for blood pressure control in patients with obstructive pulmonary disease 2
Non-dihydropyridine calcium channel blockers should be avoided in decompensated heart failure as they can worsen outcomes 6